Synteract CEO Steve Powell said the location – the second largest city in Wales – was chosen for the company’s next office location due to its proximity to multiple universities and “its history as a good location for clinical research professionals.”
The contract research organization (CRO) is interviewing for several positions including clinical data coordinator, statistical programmer, biostatistician, process analyst, among others, and plans to open to the office late in the second quarter of 2019.
The company in 2018 announced the creation of “therapeutic centers of development” as it looks to deepen its footprint in the mid-sized CRO market space. These centers include dermatology, neurodegenerative, oncology, pediatrics, and rare/orphan disease.
Powell told us a main driver of demand for Synteract has come from “this clear delineation of focus on these growing development areas, where Synteract is well positioned to help clients advance the innovative therapies that patients need.”
As part of this commitment, the company in July 2018 acquired the specialized dermatology CRO Cu-Tech, and the pediatrics CRO KinderPharm in November the same year.
Powell added, “We have seen increased demand in our core therapeutic areas, for both full-service, global work as well as more consultative, standalone projects.”
